DE3672924D1 - Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen. - Google Patents

Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.

Info

Publication number
DE3672924D1
DE3672924D1 DE8686901579T DE3672924T DE3672924D1 DE 3672924 D1 DE3672924 D1 DE 3672924D1 DE 8686901579 T DE8686901579 T DE 8686901579T DE 3672924 T DE3672924 T DE 3672924T DE 3672924 D1 DE3672924 D1 DE 3672924D1
Authority
DE
Germany
Prior art keywords
muteine
cystein
reduced
human tnf
tnf proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686901579T
Other languages
English (en)
Inventor
F Mark
S Lin
Yu Lu
M Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24807256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3672924(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of DE3672924D1 publication Critical patent/DE3672924D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DE8686901579T 1985-02-07 1986-02-03 Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen. Expired - Lifetime DE3672924D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/698,939 US4959314A (en) 1984-11-09 1985-02-07 Cysteine-depleted muteins of biologically active proteins
PCT/US1986/000236 WO1986004606A1 (en) 1985-02-07 1986-02-03 Cysteine-depleted muteins of biologically active human tumor necrosis factor proteins

Publications (1)

Publication Number Publication Date
DE3672924D1 true DE3672924D1 (de) 1990-08-30

Family

ID=24807256

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686901579T Expired - Lifetime DE3672924D1 (de) 1985-02-07 1986-02-03 Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.

Country Status (8)

Country Link
US (1) US4959314A (de)
EP (1) EP0213175B1 (de)
JP (1) JPS62501608A (de)
AU (1) AU5518086A (de)
DE (1) DE3672924D1 (de)
DK (1) DK172276B1 (de)
FI (1) FI99015C (de)
WO (1) WO1986004606A1 (de)

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56026B1 (en) * 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US5342614A (en) * 1984-12-21 1994-08-30 Otsuka Pharmaceutical Co., Ltd. Method of treating arthritus or inflammation with IL-1β or derivatives thereof
US6107465A (en) * 1984-12-21 2000-08-22 Otsuka Pharmaceutical Co., Ltd. IL-1β and derivatives thereof and drugs
US5516896A (en) * 1985-02-25 1996-05-14 Zymogenetics, Inc. Biologically active B-chain homodimers
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
US5859208A (en) * 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5081021A (en) * 1986-02-04 1992-01-14 Mizuno Den Ichi DNA encoding HTNF variants exhibiting enhanced activity
US5008374A (en) * 1986-03-14 1991-04-16 Otsuka Pharmaceutical Co., Ltd. IL-1α derivatives and drugs
US5900476A (en) * 1986-05-30 1999-05-04 The Scripps Research Institute Therapeutic domains of van Willebrand factor
EP0585957A1 (de) * 1986-08-06 1994-03-09 Ajinomoto Co., Inc. Rekombinanter B-Zell-Differenzierungsfaktor
US5681934A (en) * 1986-09-30 1997-10-28 Board Of Regents, The University Of Texas System 47-kilodalton antigen of Treponema pallidum
US7049131B1 (en) * 1987-02-12 2006-05-23 Genentech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
AU1346488A (en) * 1987-02-26 1988-09-26 Cetus Corporation Arginine-depleted human tumor necrosis factor
ZA884012B (en) * 1987-06-04 1989-02-22 Zymogenetics Inc Tissue plasminogen activator analogs having modified growth factor domains
DE68929273T2 (de) * 1988-08-24 2001-07-05 American Cyanamid Co Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
DE3907244A1 (de) * 1989-03-07 1990-09-13 Knoll Ag Erzeugnisse, enthaltend ein lithiumsalz und einen tumor-nekrose-faktor
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
WO1990012877A1 (en) * 1989-04-19 1990-11-01 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
US6207798B1 (en) * 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
FR2651130B1 (fr) * 1989-08-23 1991-12-13 Roussel Uclaf Sequence d'oligonucleotides anti-sens, anti-arn message du tnf alpha, procede de preparation, application a titre de medicaments et compositions pharmaceutiques.
EP0447523A4 (en) * 1989-10-10 1991-11-27 Amgen Inc. Compositions and methods for treating or preventing infections in canine and feline animals
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
RU2212411C2 (ru) * 1989-10-16 2003-09-20 Эмджен Инк. Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
US7144731B2 (en) 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
JPH05255393A (ja) * 1990-09-21 1993-10-05 Ishihara Sangyo Kaisha Ltd ポリペプチド
EP0477791B1 (de) * 1990-09-21 1996-08-07 Ishihara Sangyo Kaisha, Ltd. Polypeptid
DE69119869T2 (de) * 1990-11-23 1996-12-12 American Cyanamid Co Chimeres Fibroblasten-Wachstumsfaktor
US6833354B1 (en) * 1990-12-19 2004-12-21 Kaken Pharmaceutical Co., Ltd. Agent for the treatment of bone diseases
CA2107100A1 (en) * 1991-03-27 1992-09-28 Zaverio M. Ruggeri Therapeutic fragments of von willebrand factor
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
WO1993000107A1 (en) * 1991-06-20 1993-01-07 Rhone-Poulenc Rorer International (Holdings) Inc. Therapeutic fragments of von willebrand factor
ZA924674B (en) * 1991-07-02 1993-04-28 Imclone Systems Inc Cysteine depleted il-6 mutein
US5248604A (en) * 1991-07-22 1993-09-28 Bio-Technology General Corp. Enzymatically active recombinant human acetylcholinesterase and hosts and vectors for expression thereof
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB9204439D0 (en) * 1992-02-27 1992-04-15 Fujisawa Pharmaceutical Co A new cephalosporin c acylase
US5444151A (en) * 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
US5326695A (en) * 1992-05-15 1994-07-05 Ludwig Institute For Cancer Research Platelet derived growth factor agonists
US5349056A (en) * 1992-10-09 1994-09-20 Regeneron Pharmaceuticals Modified ciliary neurotrophic factors
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DE69434332T2 (de) * 1993-11-12 2006-02-02 Gilead Sciences, Inc., Foster City Thrombin mutanten
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
EP0785948B1 (de) * 1994-10-13 2003-04-16 Amgen Inc., Analogen des keratinozytenwachstumfaktors
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
EP0942740B1 (de) 1996-12-06 2003-08-27 Amgen Inc., Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
DE69738841D1 (de) 1996-12-23 2008-08-28 Immunex Corp Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie
EP0966480A2 (de) 1997-01-30 1999-12-29 The University Of Virginia Patent Foundation Cystein-reduzierte peptide, welche durch a3-limitierte zytotoxische lymphozyten erkannt werden, sowie anwendungen
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
KR100496063B1 (ko) * 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
DK0975754T4 (en) 1997-04-16 2016-03-21 Amgen Inc Osteoprotegerin binding proteins and their receptors
AU7383298A (en) * 1997-05-13 1998-12-08 Regents Of The University Of California, The Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
US7723473B2 (en) * 1997-06-19 2010-05-25 St. Louis University Peptide antagonists of TGF-beta family members and therapeutic uses thereof
ATE305510T1 (de) 1997-12-17 2005-10-15 Immunex Corp Zelloberflächenglycoproteinen zusammenhang mit menschlicher b zell lymphomen - ulbp, dns und polypeptiden
US8101349B2 (en) 1997-12-23 2012-01-24 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells and their methods of use II
EP1051494B1 (de) 1998-01-31 2009-04-29 The University of Arkansas Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6476211B1 (en) * 1998-07-16 2002-11-05 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
AU762392B2 (en) * 1998-07-16 2003-06-26 Arca Biopharma, Inc. Methods and materials relating to novel CD39-like polypeptides
US6387645B1 (en) 1998-07-16 2002-05-14 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6447771B1 (en) * 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
EP2123292B1 (de) 1998-09-03 2016-05-04 Novartis Vaccines and Diagnostics, Inc. FGF-2 angiogenische wirksame Einheitdosis und Verfahren zu ihrer Verwendung
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US6350447B1 (en) 1999-01-29 2002-02-26 Hyseq, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6780977B1 (en) 1999-01-29 2004-08-24 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6899875B1 (en) 1999-01-29 2005-05-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6783959B1 (en) 1999-01-29 2004-08-31 Nuvelo, Inc. Methods and compositions relating to CD39-like polypeptides and nucleic acids
US6335013B1 (en) 1999-03-19 2002-01-01 Hyseq, Inc. Methods and materials relating to CD39-like polypeptides
JP2002541804A (ja) * 1999-04-09 2002-12-10 カイロン コーポレイション 分泌ヒトタンパク質
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US6703221B1 (en) * 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
US6825333B1 (en) 1999-08-20 2004-11-30 Chiron Corporation EGFH2 genes and gene products
CA2393688A1 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
DK1272213T3 (da) * 2000-04-06 2006-07-10 Seer Pharmaceuticals Llc Mikrobielt afgivelsessystem
JP2003530838A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001085208A2 (en) * 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
PT1370684E (pt) 2000-06-15 2008-09-08 Novartis Vaccines & Diagnostic Polinucleótidos ligados ao cancro do colon
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
US20030039647A1 (en) * 2000-07-14 2003-02-27 Christoph Reinhard Tetraspan protein and uses thereof
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
WO2002052047A2 (en) * 2000-12-22 2002-07-04 Mergen Ltd. Methods for identifying g-protein coupled receptors associated with diseases
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
WO2002081640A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
CA2830887C (en) 2001-06-05 2016-11-29 Curevac Gmbh Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
WO2003015697A2 (en) * 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
EP1436385A4 (de) * 2001-09-14 2005-12-14 Invitrogen Corp Dna-polymerasen und mutanten davon
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20060275747A1 (en) * 2001-12-07 2006-12-07 Hardy Stephen F Endogenous retrovirus up-regulated in prostate cancer
US20070037147A1 (en) * 2001-12-07 2007-02-15 Pablo Garcia Endogenous retrovirus polypeptides linked to oncogenic transformation
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
IL147414A0 (en) 2001-12-31 2002-08-14 Yeda Res & Dev Ifnar2 mutants, their production and use
AU2003218350A1 (en) * 2002-03-21 2003-10-08 Sagres Discovery, Inc. Novel compositions and methods in cancer
JP4761710B2 (ja) * 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US7585840B2 (en) 2002-04-10 2009-09-08 Merck Serono S.A. Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
KR20040107492A (ko) * 2002-04-10 2004-12-20 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 섬유증 질병의 치료 및/또는 예방을 위한오스테오프로테게린의 용도
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
TWI334785B (en) * 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
US8518694B2 (en) * 2002-06-13 2013-08-27 Novartis Vaccines And Diagnostics, Inc. Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
AU2003248845A1 (en) * 2002-07-12 2004-02-02 The Regents Of The University Of California Steroidogenic factor-1 protein variants and methods of making same
WO2004016282A1 (en) * 2002-07-19 2004-02-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays
US20040175359A1 (en) * 2002-11-12 2004-09-09 Desjarlais John Rudolph Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20040170982A1 (en) * 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
US20060210588A1 (en) * 2003-03-26 2006-09-21 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
WO2004084940A1 (en) * 2003-03-26 2004-10-07 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
JP4865540B2 (ja) 2003-04-08 2012-02-01 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 化学誘引物質に対する増大された感受性を有する幹細胞およびそれを産生および使用する方法
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
TWI272948B (en) 2003-05-01 2007-02-11 Ares Trading Sa HSA-free stabilized interferon liquid formulations
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
DE102004008168B4 (de) * 2004-02-19 2015-12-10 Voxeljet Ag Verfahren und Vorrichtung zum Auftragen von Fluiden und Verwendung der Vorrichtung
EP1734988A4 (de) * 2004-03-01 2009-08-05 Enzon Pharmaceuticals Inc Interferon-beta-polymerkonjugate
IL161673A0 (en) 2004-04-29 2004-09-27 Applied Research Systems Compositions and methods for therapy of chemotherapy-induced neuropathy
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
UA92146C2 (ru) * 2004-06-01 2010-10-11 Эйрэс Трейдинг С.А. Стабилизированная жидкая композиция, которая содержит интерферон
JP2008500995A (ja) 2004-06-01 2008-01-17 アレス トレーディング ソシエテ アノニム タンパク質安定化法
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
CA2583230A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP4891250B2 (ja) * 2004-11-10 2012-03-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 脱アミドされたインターフェロンβ
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2006110599A2 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cacna1e in cancer diagnosis, detection and treatment
JP2008535494A (ja) 2005-04-07 2008-09-04 サグレシュ ディスカバリー， インコーポレイテッド 癌関連遺伝子（ｐｒｌｒ）
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
CA2603671C (en) 2005-04-26 2012-03-27 Laboratoires Serono S.A. Insp163 polypeptides for the treatment or prevention of cancer and arthritis
SG195394A1 (en) 2005-05-18 2013-12-30 Biofactura Inc Compositions and methods for metabolic selection of transfected cells
EP1885858A2 (de) * 2005-05-19 2008-02-13 Bayer Schering Pharma Aktiengesellschaft Behandlung von krankheiten unter anwendung eines verbesserten regulierten expressionssystems
DOP2006000117A (es) * 2005-05-19 2007-11-30 Schering Ag Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1891088B1 (de) * 2005-06-10 2011-10-19 Ares Trading S.A. Verfahren zur reinigung eines il-18-bindenden proteins
WO2007014156A2 (en) * 2005-07-21 2007-02-01 Buck Institute For Age Research Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease
US20070026463A1 (en) * 2005-07-28 2007-02-01 Wyeth Compositions and methods of mutant Nogo-66 domain proteins
JP2009502173A (ja) * 2005-07-29 2009-01-29 ノバルティス アーゲー インビトロでのタンパク質折りたたみのための方法およびシステム
SG155183A1 (en) 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
EP1760092A1 (de) 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System für Screening von Zellen mit hoher Expression von einem interessierenden Protein
KR20080050591A (ko) * 2005-09-01 2008-06-09 아레스 트레이딩 에스.에이. 시신경염 치료
ES2336575T3 (es) 2005-09-22 2010-04-14 Biocompatibles Uk Limited Polipeptidos de fusion glp-1 (peptido-1 similar al glucagon) con resistencia aumentada a la peptidasa.
JP2009537605A (ja) 2006-05-24 2009-10-29 メルク セローノ ソシエテ アノニム 多発性硬化症を治療するためのクラドリビン・レジメン
WO2008001370A2 (en) 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd Caspase-8 and inflammation, infection and wound healing
EP2046110A4 (de) * 2006-07-07 2010-10-27 Univ Washington State Gene, die für die chavicol/eugenol-synthase aus dem kreosotbusch larrea tridentata kodieren
EP2469282A1 (de) * 2006-09-08 2012-06-27 University of Oxford Klinische Diagnose von Leberfibrose mithilfe einer neuartigen Tafel von menschlichen Serumprotein-Biomarkern
US20100028297A1 (en) * 2006-12-19 2010-02-04 Stewart Edward J Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2008125222A2 (en) * 2007-04-11 2008-10-23 Bayer Schering Pharma Aktiengesellschaft New modulation molecules for an improved regulated expression system
EP2076533B1 (de) * 2007-05-02 2014-10-08 Ambrx, Inc. Modifizierte interferon-beta-polypeptide und ihre verwendungen
US8946201B2 (en) * 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
DK2234645T3 (da) * 2007-12-20 2012-07-09 Merck Serono Sa Peg-interferon-beta-formuleringer
IL189408A0 (en) 2008-02-10 2009-02-11 Yeda Res & Dev Siva3, its preparation and pharmaceutical compositions containing it
EP2257628A4 (de) * 2008-03-04 2011-11-02 Univ Washington State Zusammensetzungen und verfahren zur differentiellen regulation der ungesättigtkeit von fettsäuren in membranlipiden und samenöl
PL2288715T3 (pl) 2008-04-11 2015-03-31 Merrimack Pharmaceuticals Inc Łączniki będące albuminą surowicy ludzkiej i ich koniugaty
BRPI0910686A2 (pt) 2008-04-21 2015-09-29 Tissue Regeneration Therapeutics Inc células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos.
WO2010033507A1 (en) * 2008-09-16 2010-03-25 St. Louis University Method of enhancing tgf-beta signalling
BRPI0921586A2 (pt) 2008-11-18 2019-09-24 Merrimack Pharmaceuticals Inc articuladores de albumina de soro humana e conjugados destes
US9074005B2 (en) * 2009-01-02 2015-07-07 Washington State University Compositions and methods for modulating plant disease resistance and immunity
CN201397956Y (zh) * 2009-03-23 2010-02-03 富士康(昆山)电脑接插件有限公司 电连接器组件
JP5813630B2 (ja) * 2009-05-14 2015-11-17 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード 微量ヒト血漿タンパク質バイオマーカーの新規なパネルを使用した肝線維症の臨床診断
EP2440251A4 (de) 2009-06-09 2013-01-16 Defyrus Inc Verabreichung von interferon zur prophylaxe gegen oder zur behandlung von krankheitserregenden infektionen
US20110016548A1 (en) * 2009-07-16 2011-01-20 University Of Southern California Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2694550B1 (de) 2011-04-01 2019-11-27 Universität Stuttgart Rekombinante polypeptidmitglieder der tnf-ligandenfamilien mit antikörperbindungsdomäne und verwendungen dafür
ES2563737T3 (es) 2011-05-20 2016-03-16 Ares Trading S.A. Composiciones de IFN-beta, métodos de preparación y usos de las mismas
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2791160B1 (de) 2011-12-16 2022-03-02 ModernaTX, Inc. Modifizierte mrna zusammensetzungen
EP2832856A4 (de) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd Anti-lamp5-antikörper und verwendung davon
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
EP2920212A4 (de) * 2012-11-15 2016-07-27 Esperance Pharmaceuticals Inc Fusionskonstrukte aus dem follikelstimulierenden hormon (fsh) und einer lytischen domäne sowie verfahren zur herstellung und verwendung davon
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
DK2953634T3 (da) 2013-02-07 2021-08-30 Massachusetts Gen Hospital Fremgangsmåder til udvidelse eller udtømning af regulerende t-celler
EP2971165A4 (de) 2013-03-15 2016-11-23 Moderna Therapeutics Inc Entfernung von dna-fragmenten in mrna-herstellungsverfahren
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2925021A1 (en) 2013-11-01 2015-05-07 Curevac Ag Modified rna with decreased immunostimulatory properties
JP6941561B2 (ja) 2014-10-09 2021-09-29 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 免疫障害を処置するための複数の可変ｉｌ−２用量レジメン
CN108929383B (zh) * 2017-05-26 2021-10-15 阿思科力(苏州)生物科技有限公司 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用
WO2023122716A1 (en) 2021-12-22 2023-06-29 Vanderbilt University Next generation transpososomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4816566A (en) * 1983-06-01 1989-03-28 Hoffmann-La Roche, Inc. Polypeptides having interferon activity
IL71951A0 (en) * 1983-06-01 1984-09-30 Hoffmann La Roche Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
CA1265444A (en) 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
DE3582183D1 (de) 1984-03-06 1991-04-25 Dainippon Pharmaceutical Co Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
US4879226A (en) 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
GR851626B (de) 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
WO1986004606A1 (en) 1986-08-14
FI864036A (fi) 1986-10-06
US4959314A (en) 1990-09-25
EP0213175A1 (de) 1987-03-11
DK478786A (da) 1986-12-08
EP0213175B1 (de) 1990-07-25
FI99015B (fi) 1997-06-13
FI99015C (fi) 1997-09-25
DK172276B1 (da) 1998-02-16
DK478786D0 (da) 1986-10-07
FI864036A0 (fi) 1986-10-06
AU5518086A (en) 1986-08-26
JPS62501608A (ja) 1987-07-02

Similar Documents

Publication Publication Date Title
DE3672924D1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
DK540289D0 (da) Protein
DE3586313T2 (de) Konjugate von pharmazeutisch nuetzlichen proteinen.
DE3786767D1 (de) Neues polypeptid.
NO871409L (no) Fusjonsprotein.
DE3685626T2 (de) Sequenzierung von peptiden.
DK224886A (da) Proteinbestemmelse
DE3683186D1 (de) Rekombinantes humaninterleukin-1.
DE3686130T2 (de) Geschmackskontrolle von proteinhydrolysaten.
DK275788D0 (da) Protein
DK38989D0 (da) Dna-sekvens
DK499886A (da) Peptid
DK600586D0 (da) Protein
NO169173C (no) Veksthormon-frigjoerende peptider
DE3684947D1 (de) Faktor-ix-protein.
DK354487A (da) Oncogen-relaterede peptider
DK419486D0 (da) Proteinekspression
DK395288D0 (da) Proteiner
DE69228669D1 (de) Proteinsequenzierung
DE3685636T2 (de) Lysozymbetreffende peptide.
MC1830A1 (fr) Peptides
DK578189A (da) Dna-sekvens
DE3782199T2 (de) Biologisch aktive peptide tan-866.
ATE54941T1 (de) Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen.
DK694287D0 (da) Overfladeaktivt rekombinant-alveolaerprotein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV